Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization
- PMID: 16009163
- DOI: 10.1016/j.fertnstert.2004.12.053
Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization
Abstract
Objective: To determine whether the serum concentration of hCG on the day after hCG administration (abbreviated throughout this article as [hCG]) is related to the incidence of ovarian hyperstimulation syndrome (OHSS), oocyte recovery per follicle, fertilization, blastulation, embryo transfer, implantation, and clinical pregnancy.
Design: Retrospective study.
Setting: Private infertility clinic.
Patient(s): The OHSS study group included 849 non-donor IVF cycles performed between January 1998 and August 2003. The study group for hCG efficacy included 248 nondonor IVF cycles performed between January 2001 and May 2003 with patients younger than 35 years of age.
Intervention(s): None.
Main outcome measure(s): Occurrence of OHSS, severity of OHSS, [hCG], proportion of follicles yielding oocytes, fertilization rate, blastulation rate, transfer rate, implantation rate, and clinical pregnancy rate.
Result(s): No significant relationships were observed between [hCG] and the proportion of follicles yielding oocytes, fertilization rate, blastulation rate, or the probabilities of embryo transfer, implantation, or clinical pregnancy. The incidence of OHSS (all types) and OHSS requiring transvaginal paracentesis were predicted by [hCG] (P=.02 and P=.05, respectively) and with follicle count (P<.0001 in both cases).
Conclusion(s): These results suggest that moderated hCG dosage is useful in preventing OHSS without reducing efficacy.
Similar articles
-
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.Fertil Steril. 2004 Oct;82(4):841-6. doi: 10.1016/j.fertnstert.2004.03.055. Fertil Steril. 2004. PMID: 15482757
-
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.Fertil Steril. 2006 Jan;85(1):112-20. doi: 10.1016/j.fertnstert.2005.07.1292. Fertil Steril. 2006. PMID: 16412740 Clinical Trial.
-
Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.Eur J Obstet Gynecol Reprod Biol. 2005 Sep 1;122(1):79-84. doi: 10.1016/j.ejogrb.2005.01.023. Eur J Obstet Gynecol Reprod Biol. 2005. PMID: 16154042 Clinical Trial.
-
[Therapeutic induction of ovulation: towards the replacement of hCG with LH].Contracept Fertil Sex. 1994 Jul-Aug;22(7-8):459-67. Contracept Fertil Sex. 1994. PMID: 7920947 Review. French.
-
Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.Semin Reprod Med. 2010 Nov;28(6):475-85. doi: 10.1055/s-0030-1265674. Epub 2010 Nov 16. Semin Reprod Med. 2010. PMID: 21082506 Review.
Cited by
-
Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.J Assist Reprod Genet. 2009 May;26(5):251-6. doi: 10.1007/s10815-009-9326-6. Epub 2009 Jul 23. J Assist Reprod Genet. 2009. PMID: 19629674 Free PMC article. Clinical Trial.
-
Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle.Clin Exp Reprod Med. 2014 Sep;41(3):140-5. doi: 10.5653/cerm.2014.41.3.140. Epub 2014 Sep 30. Clin Exp Reprod Med. 2014. PMID: 25309860 Free PMC article.
-
Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.Endocr Rev. 2018 Oct 1;39(5):593-628. doi: 10.1210/er.2017-00236. Endocr Rev. 2018. PMID: 29982525 Free PMC article. Review.
-
Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study.Drug Des Devel Ther. 2016 May 18;10:1691-4. doi: 10.2147/DDDT.S105607. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27274202 Free PMC article.
-
A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.Endocrinology. 2009 Aug;150(8):3807-14. doi: 10.1210/en.2009-0107. Epub 2009 May 14. Endocrinology. 2009. PMID: 19443574 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources